These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35859597)

  • 1. Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wang R; Ye H; Ma L; Wei J; Wang Y; Zhang X; Wang L
    Front Cardiovasc Med; 2022; 9():890481. PubMed ID: 35859597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
    BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction.
    Medeiros P; Coelho C; Costa-Oliveira C; Rocha S
    Cureus; 2023 Feb; 15(2):e34508. PubMed ID: 36874318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials.
    Song Y; Zhao Z; Zhang J; Zhao F; Jin P
    Front Cardiovasc Med; 2022; 9():922721. PubMed ID: 35990952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials.
    Liu XH; Wang GL; Xu Q; Zhang L; Liu HJ
    Front Cardiovasc Med; 2022; 9():943377. PubMed ID: 36148074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials.
    Rindone JP; Mellen CK; Goldenstein M
    Hosp Pharm; 2024 Jun; 59(3):282-287. PubMed ID: 38764991
    [No Abstract]   [Full Text] [Related]  

  • 7. Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Bhattacharjee P; Khan Z
    Cureus; 2023 Nov; 15(11):e48674. PubMed ID: 38090453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction.
    Zhou X; Zhu H; Zheng Y; Tan X; Tong X
    Front Cardiovasc Med; 2022; 9():953948. PubMed ID: 36304540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
    Xiong B; Nie D; Qian J; Yao Y; Yang G; Rong S; Zhu Q; Du Y; Jiang Y; Huang J
    ESC Heart Fail; 2021 Dec; 8(6):4852-4862. PubMed ID: 34716749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sacubitril-valsartan on left ventricular remodeling in patients with acute myocardial infarction after primary percutaneous coronary intervention: a systematic review and meta-analysis.
    Liu Y; Sun Y; Dai W
    Front Pharmacol; 2024; 15():1366035. PubMed ID: 38863978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis.
    Kotak S; Hassan W; Mehmood M; Kumar U; Sagreeka F; Karishma F; Kumari P; Pirya F; Saquib J; Iqbal A; Khan AA; Varrassi G; Khatri M; Kumar S
    Cureus; 2023 Oct; 15(10):e46547. PubMed ID: 37933369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sacubitril-valsartan vs. angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in preventing atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.
    Baía Bezerra F; Rodrigues Sobreira LE; Tsuchiya Sano VK; de Oliveira Macena Lôbo A; Cavalcanti Orestes Cardoso JH; Alves Kelly F; Aquino de Moraes FC; Consolim-Colombo FM
    Herz; 2024 Sep; ():. PubMed ID: 39313691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Angiotensin Receptor-Neprilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-analysis.
    Mujadzic H; Prousi GS; Napier R; Siddique S; Zaman N
    J Innov Card Rhythm Manag; 2022 Sep; 13(9):5164-5175. PubMed ID: 36196235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis.
    Xiang Q; Wang M; Ding Y; Fan M; Tong H; Chen J; Yu P; Shen L; Chen X
    Front Pharmacol; 2022; 13():832782. PubMed ID: 35444529
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.
    Gao J; Zhang X; Xu M; Deng S; Chen X
    Front Pharmacol; 2023; 14():1237210. PubMed ID: 37601056
    [No Abstract]   [Full Text] [Related]  

  • 17. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/valsartan and arrhythmic burden in patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.
    Pozzi A; Abete R; Tavano E; Kristensen SL; Rea F; Iorio A; Iacovoni A; Corrado G; Wong C
    Heart Fail Rev; 2023 Nov; 28(6):1395-1403. PubMed ID: 37380925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
    Gilstrap L; Zipkin RJ; Barnes JA; King A; O'Malley AJ; Gaziano TA; Tosteson ANA
    Am Heart J; 2022 Aug; 250():23-28. PubMed ID: 35525261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.